Explore

CRISPR Therapeutics and ViaCyte Initiate VCTX210 Clinical Trial for Type 1 Diabetes Treatment

CRISPR Therapeutics and ViaCyte Initiate VCTX210 Clinical Trial for Type 1 Diabetes Treatment

CRISPR Therapeutics and ViaCyte have commenced the VCTX210 clinical trial, a significant step towards developing a lasting solution for Type 1 Diabetes. This trial aims to test whether gene-edited cells can restore natural insulin production in patients, potentially eliminating the need for daily insulin injections and pumps. The collaboration leverages CRISPR gene-editing technology to engineer pancreatic cells that are designed to be immune-evasive, meaning they can function within the body without being attacked by the patient's immune system. This approach seeks to overcome the major challenge of immune rejection commonly associated with traditional cell transplants, which often requires lifelong immunosuppression. The first patient has already received the VCTX210 treatment, marking a critical milestone in the study.

Taysha Gene Therapies Reports Positive Clinical Trial Results for Rett Syndrome Treatment TSHA-102

Taysha Gene Therapies Reports Positive Clinical Trial Results for Rett Syndrome Treatment TSHA-102

Taysha Gene Therapies Reports Positive Clinical Trial Results for Rett Syndrome Treatment TSHA-102

Congressman Jake Ellzey Urged to Support Bipartisan Alzheimer's Screening and Prevention Act

Congressman Jake Ellzey Urged to Support Bipartisan Alzheimer's Screening and Prevention Act

Congressman Jake Ellzey is being encouraged to support the bipartisan Alzheimer’s Screening and Prevention Act (ASAP). This legislation aims to create a pathway for Medicare coverage of FDA-approved blood tests designed to detect Alzheimer’s biomarkers. Currently, Medicare regulations prevent coverage for dementia screening tests in individuals who do not yet exhibit symptoms. The ASAP Act seeks to address this gap, enabling earlier detection of Alzheimer's disease. A simple blood test can now identify Alzheimer's before symptoms manifest, representing a significant scientific advancement. However, fewer than 10% of individuals with mild cognitive impairment receive a diagnosis early enough to benefit from existing FDA-approved treatments. In Texas, where Congressman Ellzey serves District 6, 11.9% of adults over 65 are living with Alzheimer’s, a figure that is on the rise. The proposed act would offer a more scalable and accessible diagnostic approach compared to previous methods.

Teva Pharmaceuticals' Ecopipam for Pediatric Tourette Syndrome Accepted for FDA Priority Review

Teva Pharmaceuticals' Ecopipam for Pediatric Tourette Syndrome Accepted for FDA Priority Review

Teva Pharmaceuticals' Ecopipam for Pediatric Tourette Syndrome Accepted for FDA Priority Review

Walmart, Harris Teeter recall fruit bars over glass risk

Walmart, Harris Teeter recall fruit bars over glass risk

Five flavors and a variety pack are affected by the nationwide recall.

Ultragenyx Secures First Gene Therapy Approval for Glycogen Storage Disease Type Ia

Ultragenyx Secures First Gene Therapy Approval for Glycogen Storage Disease Type Ia

Ultragenyx has received accelerated approval from the U.S. Food and Drug Administration (FDA) for its first gene therapy, pariglasgene brecaparvovec-opnr, now branded as Genglycos. This therapy is designed to treat glycogen storage disease type Ia (GSDIa) in adults and children over the age of eight. GSDIa is a rare genetic disorder caused by a deficiency of the G6PC enzyme, which is crucial for releasing glucose from the liver. Genglycos, a one-time AAV8 gene therapy, aims to deliver a functional G6PC gene to the liver, restoring the enzyme and helping to stabilize blood sugar levels. The approval follows a successful late-stage study where Genglycos significantly reduced the daily cornstarch intake required by patients, a common treatment for GSDIa.

Roger Stone Lobbies for Vape Firm Ecto World Amidst Legal Challenges and Regulatory Scrutiny

Roger Stone Lobbies for Vape Firm Ecto World Amidst Legal Challenges and Regulatory Scrutiny

Roger Stone, a long-time adviser to President Trump, has been retained as a lobbyist by Ecto World, a vape product distributor facing multiple legal challenges and accusations of illegal marketing to minors. Ecto World, which operates under the name Demand Vape, has been accused by New York state and city officials of illegally distributing and selling flavored disposable nicotine products, many of which are produced in China. New York Governor Kathy Hochul announced an investigation found the company illegally shipped massive quantities of vape products, with criminal charges to be pursued. New York State Attorney General Letitia James also sued Ecto World and other vape companies for targeting children and fueling the youth vaping epidemic. Stone's lobbying efforts, for which he has been compensated at least $300,000, are focused on the Executive Office of the President regarding the regulation of e-cigarettes and related products. Matthew Glauser, president of Ecto World, stated that Stone was hired to ...

Generative AI Poised to Revolutionize Cancer Drug Trials, Addressing Recruitment Failures and Costly Development

Generative AI Poised to Revolutionize Cancer Drug Trials, Addressing Recruitment Failures and Costly Development

The development of new cancer drugs is an arduous and expensive process, often exceeding a billion US dollars and taking nearly a decade, with a high rate of failure. A primary reason for these failures is recruitment issues in clinical trials, a problem exacerbated by the increasing fragmentation of cancer entities into molecularly-defined subgroups in the era of precision oncology. This leads to multiple trials competing for a shrinking pool of eligible patients. Generative artificial intelligence (AI) is emerging as a potential solution by creating synthetic data that is indistinguishable from real data. This AI can generate medical images, text from electronic health records, and tabular data, including laboratory parameters, genetics, and outcomes. Unlike digital twins, which are digital replicas of individual patients, synthetic data statistically mimics feature distributions to create new samples without being exact copies of original training data. This technology aims to address the challenges of ...

B. Braun Medical Inc. Recalls Excel® Lactated Ringers Injection Due to Particulate Matter

B. Braun Medical Inc. Recalls Excel® Lactated Ringers Injection Due to Particulate Matter

B. Braun Medical Inc. has initiated a voluntary North American recall of one lot of its Excel® Lactated Ringers Injection, 1000mL, distributed to hospitals and healthcare facilities. The recall is due to the presence of particulate matter in the solution, primarily identified as cellulose cotton fibers, with some particles also being cellulose wood fiber and polystyrene. The affected product, with lot number J4H077 and an expiration date of November 30, 2026, was distributed nationwide in the U.S. and to Canada between August 29, 2024, and September 30, 2024. The product is used for hydration and fluid replacement in adult, pediatric, and neonatal patients. B. Braun has not received any reports of adverse events related to this recall to date. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration (FDA).

New Research Explores Noninvasive Nasal Drug Delivery to the Brain

New Research Explores Noninvasive Nasal Drug Delivery to the Brain

A recent study published in Experimental & Molecular Medicine has analyzed various scientific breakthroughs concerning the noninvasive delivery of drugs to the brain via nasal routes. The research highlights the significant challenge posed by the blood-brain barrier (BBB), a protective layer that prevents harmful substances from entering the brain but also obstructs therapeutic drugs. While the nose offers a fast, needle-free pathway that bypasses the BBB and avoids initial drug breakdown in the liver, its efficiency in clearing foreign substances limits drug absorption time. The study identifies three advanced delivery strategies that could protect drug molecules during their journey through the nose: nanoparticles, extracellular vesicles, and living systems like genetically engineered cells, viruses, and bacteria. These systems aim to overcome the anatomical limitations of human nasal passages, which have a much smaller olfactory epithelium compared to rodents, making direct drug delivery less effective....

Longeveron Secures $1 Million XPRIZE Healthspan Milestone Award for Stem Cell Therapy

Longeveron Secures $1 Million XPRIZE Healthspan Milestone Award for Stem Cell Therapy

Longeveron, a Miami-based regenerative medicine company, has been awarded a $1 million Milestone 2 award in the $101 million XPRIZE Healthspan competition. This recognition stems from their clinical trial data demonstrating that their lead candidate, laromestrocel, an allogeneic mesenchymal stem cell (MSC) therapy, increased the six-minute walk distance in patients with aging-related frailty. Laromestrocel is derived from the bone marrow of young, healthy adult donors and is designed for broad, one-time intervention, working through anti-inflammatory, pro-vascular, and pro-regenerative effects. The XPRIZE Healthspan competition aims to develop and test therapies that can restore muscle, cognition, and immune function lost to aging by at least ten years within a year or less of treatment. Longeveron was one of ten teams selected from over 600 international entries to advance to this milestone.

FDA Selects Cadence's HypertensionOS for TEMPO Pilot Program to Evaluate Digital Health Technology

FDA Selects Cadence's HypertensionOS for TEMPO Pilot Program to Evaluate Digital Health Technology

The U.S. Food and Drug Administration (FDA) has chosen Cadence's HypertensionOS as the second participant in its Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot program. HypertensionOS is a software as a medical device (SaMD) designed to assist clinicians in managing medication for patients diagnosed with stage 2 hypertension. This selection is part of a broader FDA initiative, in collaboration with the Centers for Medicare & Medicaid Services (CMS) Innovation Center’s Advancing Chronic Care with Effective, Scalable Solutions (ACCESS) Model. The TEMPO pilot aims to facilitate access to specific digital health technologies while ensuring patient safety and gathering real-world evidence on their clinical application. HypertensionOS incorporates AI-assisted features to support licensed healthcare professionals, such as physicians and Advanced Practice Registered Nurses, in medication initiation and titration workflows within predefined eligibility conditions and deterministic safety checks for ou...